You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Facing questions over data security in the US and Ireland, the company has changed its name as it looks to shed its China operations.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.
RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.
Last week, GenomeWeb's readers were most interested in a judge granting Illumina a preliminary injunction to prevent BGI from distributing its sequencing platforms in the US.
The companies are developing a lung cancer liquid biopsy assay that will run on desktop sequencers, with plans to apply for regulatory clearance in China.
BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.
The company sells a number of next-generation sequencing-based tissue and liquid biopsy tests for cancer therapy selection to the Chinese market.
By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.
The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.
Study subjects of both sexes who had low germline mutation rates lived nearly five years longer than individuals with high mutation rates.
The tests are designed to detect regions in the SARS-CoV-2 genome in respiratory samples or antibodies against the virus in human serum, plasma, or blood.
Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.
News items for the week of June 15, 2020.
Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.
Progenity recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.
The firm has granted the underwriters an option to purchase up to 2,400,000 additional shares, which would contribute additional gross proceeds of up to $38.4 million.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.
Using array-based genotyping profiles for COVID-19 cases and controls, researchers identified loci on chromosomes 3 and 9 that are linked to cases with respiratory failure.
The timing of the divergence of the Measles morbillivirus and Rinderpest morbillivirus lineages traces to about when human populations began to live in cities.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
The deal expands Illumina's cloud-based data analysis portfolio and gives its customers access to tools to boost assay and operational efficiency.
The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.
Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.
The UK is implementing COVID-19 testing with a 90-minute turnaround time.
In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.